Sponsored · Video
Rgenix Cancer Therapeutics Company Focuses on RNA to Identify Novel Targets
Co-founders of Rgenix, CEO Masoud Tavazoie and COO David Darst, speak at BIO-Europe® 2019 in Hamburg about their clinical-stage cancer therapeutics company that focuses on the RNA space to identify novel cancer pathways and targets. Tavazoie describes how they begin with an in-depth understanding of tumor biology and these novel targets, and then use genetic data and samples from patients to validate their potential as targets for novel therapeutics. Rgenix is developing several of such innovative drugs in the clinic, and Darst goes into detail on how they decide on a development path to achieve the best outcome for patients and shorten the time to approval.